Dr. Reddy's Laboratories (RDY) Earnings Date & Reports
Dr... Show more
RDY is expected to report earnings to rise 263.77% to 10 cents per share on July 29
Dr. Reddy's Laboratories (RDY) Q4 FY26 Earnings Recap: One-Off Charges Drive Sharp Profit Drop
Key Takeaways
- Dr. Reddy's Laboratories reported Q4 FY26 revenues of INR 75,162 million, down 11.6% YoY and 13.9% QoQ, missing consensus estimates of around $887 million.
- Profit after tax fell 86% YoY to INR 2,201 million due to one-off items totaling over INR 7,000 million, including a INR 4,530 million shelf stock adjustment (SSA) on U.S. lenalidomide sales.
- Full-year FY26 revenues rose 3.2% YoY to INR 335,933 million, with adjusted figures showing 4.6% growth excluding one-offs; diluted EPS was INR 51.42.
- North America generics revenues plunged 51% YoY in Q4 amid lenalidomide (gRevlimid) erosion and SSA, partially offset by growth in India and emerging markets.
- Gross margin contracted to 44.8% from 55.6% YoY due to product mix and pricing pressures; adjusted gross margin was 48.0%.
- Board recommended a final dividend of INR 8 per share (800% on face value); shares fell ~5% post-earnings on the ADR (RDY).
Earnings Context and Why It Matters
Dr. Reddy's Laboratories (RDY), a leading global generics and biosimilars player, released its Q4 FY26 and full-year results on May 12, 2026, capping a fiscal year ended March 31, 2026. This report is critical amid ongoing U.S. generics pricing pressures and lenalidomide patent erosion, which have challenged North America revenues (51% of Global Generics). Prior quarters showed resilience with base business growth, but Q4 one-offs amplified headwinds. For investors, it highlights underlying strength in India (double-digit growth), Europe, and emerging markets, while underscoring pipeline progress in biosimilars as a growth driver. The results influence valuation in a competitive pharma landscape, where margins and R&D (7-8% of sales) remain key focus areas.
Q4 FY26 consolidated revenues totaled INR 75,162 million ($801 million at convenience rate), down 11.6% YoY from INR 85,060 million and 13.9% QoQ from INR 87,268 million, below analyst expectations of ~INR 82,200 million ($887 million). Excluding the INR 4,530 million SSA on U.S. lenalidomide, adjusted revenues were INR 79,692 million, down 6.3% YoY.
Profit after tax attributable to owners was INR 2,201 million, down 86% YoY from INR 15,873 million, with diluted EPS of INR 2.64 (vs. consensus ~$0.09 or INR ~8). This missed sharply due to one-offs: SSA (INR 4,530 million revenue impact), impairments on CAR-T (INR 1,291 million) and Eftilagimod Alfa (INR 914 million) programs, VAT provisions (INR 1,141 million), and New Labour Codes costs (INR 1,170 million). Adjusted PBT margin was 12.5%, EBITDA INR 9,807 million (13.0%; adjusted 19.5%). Gross margin fell to 44.8% (adjusted 48.0%).
Global Generics (87% of revenues) drove declines, with North America down 51% YoY on lower gRevlimid volumes/pricing and SSA; base business (ex-Revlimid) grew double-digits. PSAI (15%) was stable. Full FY26: revenues up 3.2% YoY (adjusted +4.6%), PAT INR 42,850 million (down 24% reported; adjusted stronger), diluted EPS INR 51.42. No specific FY27 guidance, but focus on biosimilars pipeline and margin recovery.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.
Market Reaction and Investor Sentiment
RDY shares dropped ~5% post-earnings, closing down 5.24% at $12.45 on May 12, 2026, with premarket declines up to 5.7% to $12.39 amid revenue miss and one-off drags. Sentiment turned cautious on U.S. generics weakness (lenalidomide erosion, SSA), overshadowing base business resilience and FY26 record revenues. Implied volatility suggested 5-7% moves, aligning with historical post-earnings swings. Investors parsed adjusted metrics positively but focused on near-term pressures.
Forward Outlook and Key Factors to Monitor
Following Q4 FY26, Dr. Reddy's emphasized base business resilience (double-digit growth ex-Revlimid) and strategic priorities for FY27, including biosimilars launches (e.g., semaglutide, abatacept), peptides, consumer health, and complex generics. No numeric guidance was provided, but management targets gross margins above 50% via cost efficiencies, product mix optimization, and new launches.
Key watch areas include U.S. generics stabilization post-patent cliffs, with pricing pressures potentially easing but competition rising. India formulations (15-16% sustainable growth) and emerging markets (32% Q3 growth) offer offsets. R&D spend (7-8% of revenues) supports 100+ molecules in pipeline; M&A/in-licensing to augment organics. Europe NRT EBITDA ~25% targeted.
Balance sheet strength (net cash INR 3,271 crore) enables investments; capex FY26 was focused on biosimilars. Monitor regulatory approvals, forex (INR/USD), and VAT resolutions. Operational leverage from efficiencies could lift EBITDA margins to ~23-25% adjusted. Pipeline milestones and Q1 FY27 trends will signal sustained value creation amid industry dynamics.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Advertisement
General Information
a developer of pharmaceuticals
Industry PharmaceuticalsGeneric